Elevance Health, Inc. (ELV) · Sep 10, 2026 · Guidance
Guidance reaffirmed — Adjusted EPS at least $27.00, unchanged from the Q2 guidance raise
Elevance kept its 2026 earnings floor unchanged at $27 adjusted EPS. The filing confirms stability, not another upgrade.
The filing confirms the existing outlook rather than changing it. Elevance says officers will reaffirm full-year 2026 shareholders’ earnings of at least $20.10 per diluted share, including approximately $6.90 per share of net unfavorable items.
| Metric | 2026 outlook | Market context |
|---|---|---|
| Reported shareholders’ earnings | At least $20.10 per diluted share | Unchanged from prior guidance |
| Net unfavorable items | Approximately $6.90 per diluted share | Included in reported outlook |
| Adjusted shareholders’ earnings | At least $27.00 per diluted share | Same floor established after Q2 |
The adjusted-earnings floor remains the key number, and it was already known. The company continues to expect adjusted shareholders’ earnings of at least $27.00 per diluted share. That $27.00 floor was raised with the second-quarter results, so today’s filing preserves the improved outlook but does not add another increase.
Net read: stable, not incremental. The filing reduces concern that the post-Q2 outlook had deteriorated, but it does not constitute a fresh beat or upgrade versus the standing expectation. With no new financial data, new cost assumptions, or higher target, the appropriate scorecard is guidance reaffirmed and the information is effectively priced in.
Q3 earnings report, late October
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!